Enzalutamide Plus Abiraterone May Have Higher Response Rate Together + PCa Cancer Clinical Trial Search!

Hi Guys,

Article 1)  As we already know, Enzalutamide and Abiraterone are both major breakthroughs in prostate cancer.   The combination of Enzalutamide plus Abiraterone acetate may lead to more profound suppression of androgen signaling than with either agent alone!

Article 2)  Here is a current list of new and upcoming clinical trials for PCa.   All new and potential PCa breakthroughs come exclusively from clinical trials before FDA grants approval for release.  This sight offers 1777 clinical trials around the world.  Many are here in the U.S.  Most of the new PCa breakthroughs should come from this pool of trials.
#1)  Enzalutamide Plus Abiraterone May Have Higher Response Rate
“These findings confirm the hypothesis that co-targeting mCRPC with enzalutamide and abiraterone acetate avoids the adaptive response observed with either agent alone and suggest that the combination may have a more profound response rate than either agent alone and that it is well tolerated,” the researchers concluded. Discussant Gerhardt Attard, MD, PhD, Cancer Research UK Clinical Scientist, Royal Marsden NHS Foundation Trust, UK, agreed with MD Anderson investigators that their study confirms the tolerability of the combination”.

Full Article: Enzalutamide Plus Abiraterone

#2)  PCa Cancer Clinical Trial Search!  This list shows all 1777 clinical trials for Prostate cancer.  Worth looking through.

Full List: PCa clinical trials

Remember, Lost time can never be found!

Craig Becker

The New Denver Men’s Club

Blog: https://newdenvermensclub.wordpress.com/
“Men Fighting Cancer To Win”


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s